Erratum


S. Lesvena,*, J.-F. Gautierc, R. Maréchaudb

a Service d’endocrinologie, diabétologie et maladies métaboliques, CHU de la Cavale-Blanche, boulevard Tanguy-Prigent, 29609 Brest cedex, France
b Service de médecine interne-endocrinologie-maladies métaboliques, cité hospitalière de la Milétrie, CHU de Poitiers, 86021 Poitiers cedex, France
c Service de diabétologie et d’endocrinologie, hôpital Saint-Louis, AP–HP, 1, avenue Claude-Vellefaux, 75475 Paris cedex 10, France

The publisher wishes to apologize for a last minute correction given by the authors that has not been taken in the printed and on-line version of the article.

On page 507, at the end of 2.3 RECORD or the safety of rosiglitazone, the authors have modified the last paragraph started with “In light of all these data, […] and have replaced it by the following one:

“Since September 2010, the European Medicines Agency (EMA) recommends suspension of marketing authorization to rosiglitazone. The suspension follows the re-evaluation by the European Medicines Evaluation for Human Use (CHMP), which concluded that, the benefit/risk assessment was not favorable due to the increased cardiovascular risk. The reassessment of recent data, announced last July, confirmed the increased cardiovascular risk, mainly the occurrence of myocardial infarction and stroke in relation to the expected benefits of reducing glycemia”.

The authors also wanted to mention the following conflicts of interest:

- Sandra Lesven:
  - conferences: invited as speaker for the following companies: Lilly, Novo Nordisk,
  - conferences: invited as auditor, main expenditures by the following companies: Lilly, Novo Nordisk, Sanofi-Aventis;
- Richard Maréchaud:
  - conferences: invited as scientific expert or speaker and/or study investigator for the following companies: AstraZeneca / Bristol-Myers Squibb, GlaxoSmithKline, Lilly, MSD, Novo-Nordisk, Les Laboratoires Servier.

PII of original article:S0003-4266(10)00190-3

* Corresponding author.
E-mail address: sandra.lesven@chu-brest.fr (S. Lesven).